Skip to main content

BDR Pharmaceutical launches first generic to treat Prostate cancer in India

BDR Pharmaceutical on Tuesday announced that it has launched the first generic Apalutamide (Brand name APATIDE) in India to treat metastatic castration-sensitive Prostrate cancer and non-metastatic castration-resistant Prostrate cancer.

According to the company, the product will be available across India and shall be of 60 mg strength and available in two packs – 60 tabs and 120 tabs.

The price for a bottle of 60 tablets is Rs 22,500 and for a bottle of 120 tablets is Rs 45,000.

Apalutamide in combination with anti-androgen therapy will significantly improve chances for survival within Metastatic Castration Sensitive Prostrate Cancer patients, the company claims.

“The first generic drug Apalutamide for the treatment of prostate cancer is affordable and has reduced the cost by one-third compared to the previous product. Apalutamide will significantly improve overall survival (OS) and radiographic progression-free survival with in patients.The medication reduces the risk of disease progression or death by 71% and increases life expectancy by 2 years,” 

The company claims that Apalutamide will play a role in significantly improving overall survival (OS) and radiographic progression-free survival in patients.

The company also informed that the outcome of the study indicates that the drug can contribute to the overall health-related quality of life with its addition to androgen-deprivation therapy.

“Early identification of newer molecules for life-threatening diseases encourages us to advance the development and introduction of products through the strength of backward integration of developing & manufacturing APIs to facilitate humankind. This type of advanced molecule in the treatment of various cancer indications is testimony towards our commitment to providing access to affordable medicines without compromising patients’ safety as well as qualitative standards. At BDR, our goal is to support the vision of the Honourable Prime Minister on being Atmanirbhar Bharat and make affordable and quality medicines accessible for the people of India,” Raheel Shah, Director Business Development, BDR Group said in a statement on Tuesday.

BDR Pharmaceuticals, a key player in the manufacturing of Indian Cancer medicines, has contributed to the treatment of Prostate Cancer starting with Abiraterone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.

The group focuses on development in four specialized therapeutic segments – Oncology, Critical Care, Gynecology and Neurology.

Comments

Post a Comment

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcure.co.in Rahul.Morgaonkar@emcure.co.in recruitment@em
1 comment
Read more

DoE - Doctrine of Equivalents

The Doctrine of Equivalents is a legal principle that is relevant to patent law, particularly in the United States, and it helps protect inventors' rights even when minor changes or substitutions have been made to a patented invention.  When an inventor applies for a patent, the claims in the patent document define the scope of protection for the invention. These claims outline the specific elements or features of the invention that are considered unique and non-obvious. If another party copies or uses the patented invention without permission, it may be considered infringement. However, in some cases, the accused infringer may make slight modifications to the invention that fall outside the literal scope of the patented claims. The Doctrine of Equivalents comes into play here. It allows the patent holder to assert that the accused infringer's modified version is still equivalent to the patented invention and, therefore, falls within the scope of the patent protection. For the
Post a Comment
Read more

Competitive Landscape for Pharmaceutical Generic products.

Creating a competitive landscape for a pharmaceutical generic product involves analyzing the market and identifying key players, their strengths, weaknesses, and market positioning. Here's a simplified outline: **Competitive Landscape Analysis for Pharmaceutical Generic Product:** 1. **Market Overview:**    - Size of the pharmaceutical generic product market.    - Growth trends and forecasts.    - Regulatory environment and barriers to entry. 2. **Key Players:**    - List the major pharmaceutical companies producing the generic product.    - Include both global and regional players. 3. **Market Share:**    - Percentage of market share held by each major player.    - Trends in market share changes over time. 4. **Product Portfolio:**    - Types of generic products offered by each player.    - Variations in strengths, dosage forms, and delivery methods. 5. ** Competitive Advantage :**    - Identify unique selling points of each player's products.    - Cost advantages, manufacturi
Post a Comment
Read more